DESTINY-Breast09 Trial Shows Enhertu + Pertuzumab Significantly Improves PFS in 1st-Line HER2-Positive Metastatic Breast Cancer

Positive high-level results from a planned interim analysis of the DESTINY-Breast09 Phase III trial showed Enhertu (trastuzumab deruxtecan) in co...

April 23, 2025 | Wednesday | News
Roche to Invest $50 Billion in U.S. Operations, Boosting Manufacturing, R&D, and Job Creation

Roche  announced  that it will invest USD 50 billion into the United States of America in the next five years. These investments further strength...

April 23, 2025 | Wednesday | News
Leukemia & Lymphoma Society Launches Groundbreaking Pediatric Subtrial in Global PedAL Master Clinical Trial

The Leukemia & Lymphoma Society (LLS) announced the first pediatric patient has received treatment in a new subtrial of its Pediatric Ac...

April 22, 2025 | Tuesday | News
UB Spin-Off POP Biotechnologies Reports 100% Protection in Preclinical Trials of H5N1 Avian Flu Vaccine

As H5N1 avian influenza continues its spread across species and continents, a vaccine being developed by University of Buffalo (SUNY) spin-off&nb...

April 22, 2025 | Tuesday | News
Dupixent Secures FDA Nod for Chronic Spontaneous Urticaria in Patients Unresponsive to Antihistamines

Approval based on phase 3 studies demonstrating Dupixent significantly reduced itch and hives compared to placebo In the US, there are more than 300,0...

April 21, 2025 | Monday | News
Daiichi Sankyo and AstraZeneca’s ENHERTU Combo Outperforms Standard of Care in First-Line HER2+ Metastatic Breast Cancer

DESTINY-Breast09 phase 3 trial of Daiichi Sankyo and AstraZeneca’s ENHERTU is the first trial in more than a decade to demonstrate superior eff...

April 21, 2025 | Monday | News
SparX Biopharma to Present SPX-303 Clinical Progress at AACR 2025, Highlighting Dual Checkpoint Targeting in ‘Super IO’ Strategy

SparX Biopharmaceutical Corp. announced that it will present clinical updates on its lead asset, SPX-303, a first-in-class anti-LILRB2/PD-L1 bispecific ant...

April 21, 2025 | Monday | News
POP Biotechnologies' Nanoparticle Vaccine Shows 100% Protection Against H5N1 Avian Influenza in Preclinical Trials

As H5N1 avian influenza continues its spread across species and continents, a vaccine being developed by University of Buffalo (SUNY) spin-off&nb...

April 18, 2025 | Friday | News
Endevica Bio Launches Phase 2 Trial for B07, a Potential Breakthrough Treatment to Prevent Weight Loss in Cancer Patients

Endevica Bio, a privately held company developing first-in-class peptide drug candidates, announced the dose administration for the first patient in a Phas...

April 18, 2025 | Friday | News
President Trump Signs Executive Order to Lower Drug Prices, Focuses on Medicare Negotiations and Pharmacy Benefit Manager Reforms

President Trump issued an Executive Order titled Lowering Drug Prices by Once Again Putting Americans First on Tuesday, April 15. The Executive O...

April 18, 2025 | Friday | News
Actum Launches New Life Sciences Platform, Taps Top Industry Leaders to Tackle Biopharma’s Critical Challenges

Actum Pharma (Actum), a strategy and operating business partner to global biopharma manufacturers, today announces two executive appointments to launch a...

April 18, 2025 | Friday | News
Thermo Fisher Opens Doors to the Future of Cell Therapy Manufacturing in Carlsbad

Innovative 6,000-square-foot facility enables clinical and commercial process development support to help cell therapy developers transition from researc...

April 18, 2025 | Friday | News
Pfizer Applauds CDC Panel’s Expanded Recommendation for RSV Vaccination in At-Risk Adults Aged 50–59

Pfizer Inc. announced  that the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) vote...

April 17, 2025 | Thursday | News
Tariff hikes call for CPOs to keep reputational issues and costs down

At this stage, it is unknown just how much America’s new 10% tariff on the UK will cost the pharmaceutical industry. However, given that these levi...

April 17, 2025 | Thursday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close